Standout Papers
Citation Impact
Citing Papers
Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes
2015 Standout
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
2019
Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies
2018 StandoutNobel
The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis
2013
Cell type-selective secretome profiling in vivo
2020 StandoutNobel
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
From NASH to HCC: current concepts and future challenges
2019
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
2018
Limitations of non-invasive tests for assessment of liver fibrosis
2020
Non-alcoholic fatty liver disease – A global public health perspective
2018 Standout
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
2018
Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin
2020 StandoutNobel
Hepatocellular carcinoma
2016 Standout
Microbial tryptophan catabolites in health and disease
2018 Standout
Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
2018 StandoutNobel
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics
2020 Standout
Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita
2020
Hallmarks of aging: An expanding universe
2023 Standout
Steatosis and insulin resistance in response to treatment of chronic hepatitis C
2012
Mapping the molecular signatures of diet-induced NASH and its regulation by the hepatokine Tsukushi
2018
Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis
2015 Standout
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis
2020
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
2018
Hepatocellular carcinoma
2021 Standout
Mechanisms and disease consequences of nonalcoholic fatty liver disease
2021
Interaction between microbiota and immunity in health and disease
2020 Standout
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
2010
Gut microbiome, liver immunology, and liver diseases
2020
Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy
2014
Gut microbiome and health: mechanistic insights
2022 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Hepatitis C Virus Infection and Rheumatic Diseases
2016
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Sex and gender: modifiers of health, disease, and medicine
2020 Standout
Non-alcoholic fatty liver disease
2021 Standout
Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association
2021 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages
2018
Adaptive immunity: an emerging player in the progression of NAFLD
2019
Prevalence of High and Moderate Risk Nonalcoholic Fatty Liver Disease Among Adults in the United States, 1999–2016
2021
Deep learning in histopathology: the path to the clinic
2021 Standout
Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation
2018
Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism
2017 StandoutNobel
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
2014 Standout
Global burden of liver disease: 2023 update
2023 Standout
The global NAFLD epidemic
2013 Standout
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
2012
Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019
2021
Chronic hepatitis C virus infection and lipoprotein metabolism
2015
Extrahepatic Morbidity and Mortality of Chronic Hepatitis C
2015
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
2012 Standout
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Host – hepatitis C viral interactions: The role of genetics
2016
Sex differences in immune responses
2016 Standout
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
2018
A higher flavonoid intake is associated with less likelihood of nonalcoholic fatty liver disease: results from a multiethnic study
2018
HCV and the hepatic lipid pathway as a potential treatment target
2011
Inflammation in obesity, diabetes, and related disorders
2022 Standout
Hepatocellular carcinoma
2022 Standout
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
2005 Standout
The role of the microbiome in NAFLD and NASH
2018
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
2023 Standout
Hepatocellular Carcinoma
2019 Standout
The Growing Burden of Disability Related to Nonalcoholic Fatty Liver Disease: Data From the Global Burden of Disease 2007‐2017
2020
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function
2019
Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
2018 Standout
Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors
2021
The oncologic burden of hepatitis C virus infection: A clinical perspective
2017
Artificial intelligence in prediction of non‐alcoholic fatty liver disease and fibrosis
2021
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
2017 Standout
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Prevalence trends in non-alcoholic fatty liver disease at the global, regional and national levels, 1990–2017: a population-based observational study
2020
Controlled-release mitochondrial protonophore (CRMP) reverses dyslipidemia and hepatic steatosis in dysmetabolic nonhuman primates
2019
Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States
2017 Standout
2022
Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
2018
Efficacy of synbiotic supplementation in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of clinical trials: Synbiotic supplementation and NAFLD
2018
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review
2023 Standout
Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate
2015 StandoutNobel
Nonalcoholic Steatohepatitis
2020
How sex and age affect immune responses, susceptibility to infections, and response to vaccination
2015
EASL Recommendations on Treatment of Hepatitis C 2018
2018 Standout
Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD
2020
NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
2019
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
2017 Standout
Nonalcoholic Fatty Liver Disease
2015 Standout
Bile Acids as Metabolic Regulators and Nutrient Sensors
2019
Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T 1 -weighted MRI
2023 StandoutNobel
Important Flavonoids and Their Role as a Therapeutic Agent
2020 Standout
Works of Mohammed Eslam being referenced
ADAPT: An Algorithm Incorporating PRO‐C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis
2018
Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study
2018
Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
2019
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission
2019
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
2017 Standout
The changing epidemiology of liver diseases in the Asia–Pacific region
2018
Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008
2010
Genetic Insights for Drug Development in NAFLD
2019
The Impact of Host Factors on Management of Hepatitis C Virus
2012
A polymorphism in the Irisin-encoding gene (FNDC5) associates with hepatic steatosis by differential miRNA binding to the 3′UTR
2018
Insulin Resistance Predicts Rapid Virologic Response to Peginterferon/Ribavirin Combination Therapy in Hepatitis C Genotype 4 Patients
2010
Genetics and epigenetics of NAFLD and NASH: Clinical impact
2017
Pioglitazone improves virological response to peginterferon α-2b/ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance
2009
Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel
2010
Thalidomide with peginterferon alfa-2b and ribavirin in the treatment of non-responders genotype 1 chronic hepatitis C patients: proof of concept
2011
Insulin resistance and hepatitis C: an evolving story
2011
Type 2 Diabetes and Metformin Use Associate With Outcomes of Patients With Nonalcoholic Steatohepatitis–Related, Child–Pugh A Cirrhosis
2020
MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
2020
The Impact of Host Factors on Management of Hepatitis C Virus
2012
2015
Meta‐analysis: insulin resistance and sustained virological response in hepatitis C
2011
Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation
2019
The Epigenetic Drug Discovery Landscape for Metabolic-associated Fatty Liver Disease
2020
The macrophage activation marker sCD 163 is associated with morphological disease stages in patients with non‐alcoholic fatty liver disease
2016
Genome-Wide Association Studies and Hepatitis C: Harvesting the Benefits of the Genomic Revolution
2015